Cargando…
An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
BACKGROUND: In our previous dose-escalation study, we uncovered the maximum tolerated dose (MTD) of weekly irinotecan was escalated to 80 mg/m(2) and 65 mg/m(2) for UDP glucuronosyltransferase family 1 member A1 (UGT1A1) *1*1 and *1*28 rectal cancer patients in neoadjuvant chemoradiotherapy (nCRT)....
Autores principales: | Guan, Yun, Shen, Yunzhu, Xu, Ye, Li, Chao, Wang, Jingwen, Gu, Weilie, Lian, Peng, Huang, Dan, Cai, Sanjun, Zhang, Zhen, Zhu, Ji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557009/ https://www.ncbi.nlm.nih.gov/pubmed/31217818 http://dx.doi.org/10.1177/1756284819852293 |
Ejemplares similares
-
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
por: Zhu, Ji, et al.
Publicado: (2020) -
Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022) -
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
por: Iwasa, Satoru, et al.
Publicado: (2021) -
CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
por: Cai, Gang, et al.
Publicado: (2015) -
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
por: Zhu, Ji, et al.
Publicado: (2013)